Evidence map›Paper›PMID 38526604›Full record

ArticleMedical oncology (Northwood, London, England)2024

Bioinformatics-based screening and analysis of the key genes involved in the influence of antiangiogenesis on myeloid-derived suppressor cells and their effects on the immune microenvironment.

XiangFei Zhao, RuGang Zhao, JuYi Wen, Xia Zhang, ShanShan Wu, Juan Fang, JunPeng Ma, LiPin Gao, Yi Hu

Abstract read
PubMed Publisher
In one paragraph

Article in Medical oncology (Northwood, London, England), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.9field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 1 institution in 1 country.

XiangFei Zhao *Department of Oncology, 5th Medical Center of Chinese, PLA General Hospital, Dongdajie 8th, Fengtai District, Beijing, 100853, China.
RuGang Zhao *Department of Oncology, 5th Medical Center of Chinese, PLA General Hospital, Dongdajie 8th, Fengtai District, Beijing, 100853, China.
JuYi WenDepartment of Oncology, 5th Medical Center of Chinese, PLA General Hospital, Dongdajie 8th, Fengtai District, Beijing, 100853, China.
Xia ZhangDepartment of Oncology, 5th Medical Center of Chinese, PLA General Hospital, Dongdajie 8th, Fengtai District, Beijing, 100853, China.
ShanShan WuDepartment of Oncology, 5th Medical Center of Chinese, PLA General Hospital, Dongdajie 8th, Fengtai District, Beijing, 100853, China.
Juan FangDepartment of Oncology, 5th Medical Center of Chinese, PLA General Hospital, Dongdajie 8th, Fengtai District, Beijing, 100853, China.
JunPeng MaDepartment of Oncology, 6th Medical Center of Chinese, PLA General Hospital, Beijing, China.
LiPin GaoDepartment of Oncology, 6th Medical Center of Chinese, PLA General Hospital, Beijing, China.
Yi HuDepartment of Oncology, 5th Medical Center of Chinese, PLA General Hospital, Dongdajie 8th, Fengtai District, Beijing, 100853, China. huyi301zlxb@sina.com.ORCID http://orcid.org/0000-0001-9319-5692
Chinese PLA General Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

This study aimed to screen differentially expressed genes (DEGs) involved in the influence of antiangiogenic therapy on myeloid-derived suppressor cell (MDSC) infiltration and investigate their mechanisms of action. Data on DEGs after the action of antiangiogenic drugs in a pan-cancer context were obtained from the Gene Expression Omnibus (GEO) database. Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analyses were performed using the clusterProfiler package in R software. Single-sample gene set enrichment analysis was performed using the gene set variation analysis package to evaluate the levels of immune cells and the activity of immune-related pathways. The relationships of DEGs with the infiltration levels of MDSCs and specific immune cell subpopulations were investigated via gene module analysis. The top 10 key genes were subsequently obtained from PPI network analysis using the cytoHubba plugin of the Cytoscape platform. When the DEGs of the four datasets were intersected, a DEG in the intersection of three datasets and 12 DEGs in the intersection of two datasets were upregulated, and 28 DEGs in the intersection of two datasets were downregulated. GO and KEGG pathway enrichment analyses revealed that the DEGs were associated with multiple important signaling pathways closely related to tumor onset and development, including cell differentiation, cell proliferation, the cell cycle, and immune responses. Most downregulated genes in lung adenocarcinoma (LUAD) were positively correlated with MDSC expression. Only MGP was negatively correlated; the correlation between CACNG6 and MDSC expression was statistically insignificant. In lung squamous cell carcinoma (LUSC), the relationships of PMEPA1, PCDH7, NEURL1B, and CACNG6 with MDSC expression were statistically insignificant; MGP was negatively correlated with MDSC expression. The top 10 key genes with the highest degree scores obtained using the cytoHubba plugin of Cytoscape were AURKB, RRM2, BUB1, NUSAP1, PRC1, TOP2A, NCAPH, CENPA, KIF2C, and CCNA2. Most of these genes were upregulated in LUAD and associated with immune cell infiltration and prognosis in tumors. An analysis of the relationships between DEGs and infiltration by other specific immune cells revealed the presence of consistent patterns in the downregulated genes, which exhibited positive correlations with the levels of Th2 cells, γδ T cells, and CD56dim NK cells, and negative correlations with other infiltrating immune cells. Antiangiogenic therapy may regulate MDSC infiltration through multiple important signaling pathways closely associated with tumor onset and development, such as cell differentiation, cell proliferation, the cell cycle, and immune responses. Antiangiogenic drugs may exert effects by affecting various types of infiltrating cells associated with immune suppression.

Indexed as

Adenocarcinoma of LungLung NeoplasmsMyeloid-Derived Suppressor CellsCell CycleCell Cycle ProteinsHumansImmunotherapyMembrane ProteinsNuclear ProteinsTumor MicroenvironmentCell Cycle ProteinsMembrane ProteinsNCAPH protein, humanNuclear ProteinsPMEPA1 protein, humanAntiangiogenesisBioinformaticsDifferentially expressed genesImmune microenvironmentLung cancerMyeloid-derived suppressor cells

Identifiers

PMID38526604
OpenAlexW4393151331

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.